Pharmacogenomic Study (Adjuvant Chemotherapy)
Recruitment status was: Recruiting
To assess the role of germline polymorphisms in xenobiotic metabolism genes in toxicity profile.
To assess the role of germline polymorphisms in genes associated with DNA repair, p53 tumor suppressor gene and angiogenesis pathway in predicting recurrence and survival in gastric cancer patients treated with adjuvant chemotherapy.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Pharmacogenomic Study to Predict Toxicity and Response in Gastric Cancer Patients Treated With Adjuvant Chemotherapy|
- germline polymorphisms in xenobiotic metabolism genes in toxicity profile [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||July 2008|
|Estimated Primary Completion Date:||May 2014 (Final data collection date for primary outcome measure)|
Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
Please refer to this study by its ClinicalTrials.gov identifier: NCT01470404
|Korea, Republic of|
|Samsung Medical Center|
|Seoul, Korea, Republic of|
|Principal Investigator:||won ki kang, MD||Samsung Medical Center|